Mechanism of subclinical hypothyroidism accelerating endothelial dysfunction (Review)

The association between subclinical hypothyroidism (SH) and cardiovascular disease has received increasing attention in recent years. The predisposition of patients with SH to endothelial dysfunction, an early sign of atherosclerosis, has been observed. This predisposition may be partially explained...

Full description

Bibliographic Details
Main Authors:	LU, MING, YANG, CHONG-BO, GAO, LING, ZHAO, JIA-JUN
Format:	Online
Language:	English
Published:	D.A. Spandidos 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4247316/

id	pubmed-4247316
recordtype	oai_dc
spelling	pubmed-42473162014-12-01 Mechanism of subclinical hypothyroidism accelerating endothelial dysfunction (Review) LU, MING YANG, CHONG-BO GAO, LING ZHAO, JIA-JUN Articles The association between subclinical hypothyroidism (SH) and cardiovascular disease has received increasing attention in recent years. The predisposition of patients with SH to endothelial dysfunction, an early sign of atherosclerosis, has been observed. This predisposition may be partially explained by the factors also found in patients with SH, including changes in lipid profile, low grade chronic inflammation, oxidative stress and insulin resistance. The proportional risks of endothelial dysfunction to thyroid stimulating hormone (TSH) also indicate that the action of TSH on extra thyroidal-stimulating hormone receptor (TSHR) is a possible mechanism underlying the correlation, which has later been supported by the associated basic studies. L-thyroxine replacement therapy appears to improve the aforementioned aspects, whereas there remain certain controversies, particularly for the elderly. Thus, more study data are required to confirm the benefit of L-thyroxine treatment for patients with SH. D.A. Spandidos 2015-01 2014-10-27 /pmc/articles/PMC4247316/ /pubmed/25452768 http://dx.doi.org/10.3892/etm.2014.2037 Text en Copyright © 2015, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	LU, MING YANG, CHONG-BO GAO, LING ZHAO, JIA-JUN
spellingShingle	LU, MING YANG, CHONG-BO GAO, LING ZHAO, JIA-JUN Mechanism of subclinical hypothyroidism accelerating endothelial dysfunction (Review)
author_facet	LU, MING YANG, CHONG-BO GAO, LING ZHAO, JIA-JUN
author_sort	LU, MING
title	Mechanism of subclinical hypothyroidism accelerating endothelial dysfunction (Review)
title_short	Mechanism of subclinical hypothyroidism accelerating endothelial dysfunction (Review)
title_full	Mechanism of subclinical hypothyroidism accelerating endothelial dysfunction (Review)
title_fullStr	Mechanism of subclinical hypothyroidism accelerating endothelial dysfunction (Review)
title_full_unstemmed	Mechanism of subclinical hypothyroidism accelerating endothelial dysfunction (Review)
title_sort	mechanism of subclinical hypothyroidism accelerating endothelial dysfunction (review)
description	The association between subclinical hypothyroidism (SH) and cardiovascular disease has received increasing attention in recent years. The predisposition of patients with SH to endothelial dysfunction, an early sign of atherosclerosis, has been observed. This predisposition may be partially explained by the factors also found in patients with SH, including changes in lipid profile, low grade chronic inflammation, oxidative stress and insulin resistance. The proportional risks of endothelial dysfunction to thyroid stimulating hormone (TSH) also indicate that the action of TSH on extra thyroidal-stimulating hormone receptor (TSHR) is a possible mechanism underlying the correlation, which has later been supported by the associated basic studies. L-thyroxine replacement therapy appears to improve the aforementioned aspects, whereas there remain certain controversies, particularly for the elderly. Thus, more study data are required to confirm the benefit of L-thyroxine treatment for patients with SH.
publisher	D.A. Spandidos
publishDate	2015
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4247316/
_version_	1613161855410241536

Mechanism of subclinical hypothyroidism accelerating endothelial dysfunction (Review)

Similar Items